In response to the COVID-19 global pandemic, the largest mass vaccination campaign on record was initiated. In the United States, the Pfizer-BioNTech BNT162b2 (https://www.pfizer.com/scien ce/coron aviru s/ vacci ne/manuf actur ing-and-distr ibution) and Moderna mRNA-1273 (https://www.wsj.com/artic les/moder na-to-build -vacci ne-manuf actur ing-plant -in-afric a-11633 586400) messenger RNA (mRNA) vaccines received Emergency Use Authorization in December 2020. (1) Because patients who were immunosuppressed, including liver transplantation recipients (LTRs), were excluded from these vaccine trials, the safety and efficacy of COVID-19 vaccination in LTRs are largely unknown. Herein, we report a case of acute inflammatory demyelinating polyneuropathy (AIDP), the most common subtype of Guillain-Barré syndrome (GBS), following an initial dose of an mRNA COVID-19 vaccine in an adult LTR. Case studies such as ours defined as "experiences or observations associated with one or two individuals" are exempt from institutional review board approval at the University of Michigan.HugHes et al.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.